Alexion Pharma (ALXN) Tops Q2 EPS by 52c, Raises FY Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $3.11, $0.52 better than the analyst estimate of $2.59. Revenue for the quarter came in at $1.44 billion versus the consensus estimate of $1.28 billion.

GUIDANCE:

Alexion Pharma sees FY2020 EPS of $10.65-$10.95, versus the consensus of $10.88. Alexion Pharma sees FY2020 revenue of $5.55-5.6 billion, versus the consensus of $5.41 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
• Integra LifeSciences cuts 2026 outlook after Cincinnati flood